Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
More chemo isn't always better. The phase III IROCAS trial found that intensifying adjuvant chemotherapy with modified FOLFIRINOX offered no improvement in disease-free survival over standard FOLFOX6 in patients with high-risk stage III colon cancer. Experts say the findings reinforce that simply escalating cytotoxic therapy based on pathological risk alone isn't the path forward.
The phase III IROCAS trial has delivered a clear verdict: intensifying adjuvant chemotherapy doesn't help patients with high-risk stage III colon cancer. The trial, presented at the European Society for Medical Oncology (ESMO) annual congress and published in the Annals of Oncology, found that adding irinotecan to standard oxaliplatin-based therapy offered no meaningful benefit over the current standard of care.
Researchers enrolled 795 patients with completely resected, high-risk stage III colon cancer (pT4 and/or pN2 disease) across 93 centers in France, Canada, and Italy. Patients received either modified FOLFIRINOX or modified FOLFOX6 for 6 months. Despite adequate drug delivery, the intensified regimen came with more GI toxicity — including higher rates of diarrhea, nausea, and fatigue — without any survival payoff.
By the Numbers
Why it matters: High-risk stage III colon cancer patients face recurrence rates nearly 20 points higher than their lower-risk counterparts, making this an area of urgent unmet need. IROCAS signals that the answer likely lies beyond cytotoxic dose escalation — pointing researchers toward biomarker-driven or novel therapeutic strategies instead.
